Brinzolamide is a white powder insoluble in water, commercially formulated as a 1% ophthalmic suspension to reduce intraocular pressure (IOP). Brinzolamide empirical formula is C~12~H~21~N~3~O~5~S~3~ ([Figure 1](#f1-co-2-517){ref-type="fig"}) with a melting point of approximately 131°C ([@b9-co-2-517]; [@b51-co-2-517]). The commercially available preparation of brinzolamide is Azopt^®^ (Alcon Laboratories, Inc, Ft. Worth, Texas, USA), with a pH of approximately 7.5 and osmolarity of 300 mOsm/kg ([@b9-co-2-517]; [@b51-co-2-517]; [@b24-co-2-517]).

The efficacy of brinzolamide 0.3%--3% bid has been evaluated in several randomized double-blind, multicenter comparative clinical trials ([@b34-co-2-517]; [@b45-co-2-517]; [@b49-co-2-517], [@b49-co-2-517]; [@b53-co-2-517], [@b54-co-2-517]; [@b38-co-2-517]). A dose-response study comparing brinzolamide in concentrations of 0.3%, 1%, 2%, and 3% demonstrated mean IOP reductions of 3 mmHg (11.3%), 4.3 mmHg (16.1%), 4.4 mmHg (16.1%), and 4.2 mmHg (15.4%), respectively. When diurnal IOP was measured, brinzolamide 1% or 3% reduced IOP significantly better than brinzolamide 0.3% ([@b54-co-2-517]).

These observations suggested that the optimal therapeutic concentration for IOP reduction was 1%. Its recommended dosing frequency is 3 times daily in the US and twice daily in the EU and Japan. However, 3 phase III trials have reported that brinzolamide 1% bid and tid produced statistically significant IOP reductions from baseline, and that both treatments were clinically equivalent to one another ([@b53-co-2-517]; [@b34-co-2-517]; [@b49-co-2-517]).

Pharmacologically, brinzolamide is a highly specific, non-competitive, reversible, and effective inhibitor of carbonic anhydrase II (CA-II) ([@b10-co-2-517]), able to suppress formation of aqueous humor in the eye and thus decrease IOP. It can catalyze the reversible reaction of water and carbon dioxide (CO~2~) to form negatively charged bicarbonate ions ([@b35-co-2-517]). To achieve pharmacological effects, the near total inhibition of CA is required ([@b35-co-2-517]; [@b28-co-2-517]). Brinzolamide is cleared from the aqueous humor and cornea with half-lives of approximately 3 and 5 hours respectively. Therefore, the cornea acts as a reservoir, providing sustained release of the drug to the ciliary processes of the ciliary body long after topical dosing ([@b35-co-2-517]; [@b28-co-2-517]). In human tissues there are 7 different isoenzymatic forms. The most active isoenzymatic form is CA-II, which is found mainly in the erythrocytes, followed by kidneys, pancreas, eyes, central nervous system, and lungs ([@b35-co-2-517]). In the eye, the enzyme is expressed mainly in the ciliary processes of the ciliary body, the corneal endothelial cells, and the pigment epithelium.

In the corneal endothelium CA-II plays a role in the pumping mechanism, which helps to maintain the relatively dehydrated state of the corneal stroma. Inhibition of this mechanism may lead to the development of corneal decompensation and edema, with secondary impaired vision.

In a randomized, double-blind clinical trial, 372 glaucomatous and ocular hypertension (OH) patients received brinzolamide 1% or timolol 0.5%. After 18 months of treatment, no significant change was found in corneal thickness and corneal endothelium cell density ([@b34-co-2-517]). However, in this study only subjects with healthy corneas were included. Some concern remained in patients with compromised corneas, because in 2 published case reports corneal decompensation has been described in patients with keratopathy after treatment with dorzolamide ([@b1-co-2-517]; [@b29-co-2-517]).

After topical ocular administration systemic absorption of brinzolamide has been demonstrated in the tissues of healthy volunteers ([@b10-co-2-517]). Topically instilled brinzolamide enters the blood circulation binding preferentially to CA in the erythrocytes leaving the concentration of free brinzolamide in plasma below the quantification level. In the red cells less than 1% of CA-II activity is required to maintain physiological function ([@b34-co-2-517]). Thus in the erythrocytes the concentration of CA inhibitors (CAI) was insufficient to produce complete saturation of CA. In the kidney, free brinzolamide is not sufficient to inhibit in the proximal convoluted tubules and luminal CA; therefore systemic metabolic acidosis should not be obtained (see below). Furthermore, the low affinity of brinzolamide for the other CA isoforms and the low blood concentration may explain the low incidence of systemic adverse effects after topical administration ([@b34-co-2-517]).

Several clinical trials ([@b60-co-2-517]; [@b53-co-2-517]; [@b45-co-2-517]; [@b49-co-2-517]; [@b59-co-2-517]; [@b61-co-2-517]; [@b37-co-2-517]) have evaluated the safety of brinzolamide 1% ophthalmic suspension. The most commonly ocular adverse events were blurred vision (3%--8%), ocular discomfort (1.8%--5.9%), and eye pain (0.7%--4.0%). Other ocular adverse events occurring at an incidence of less than 3% included hyperemia, pruritus, tearing, discharge, blepharitis, keratitis, foreign body sensation, dry eye, conjunctivitis, and lid margin crusting.

Zhau and Chen (2005) have reported two cases of corneal decompensation after 15 months and 2 years of brinzolamide therapy. Corneal edema reversed with discontinuation of the treatment; however, the reason was difficult to assess, and neither patient was rechallenged after recovery. No change in central corneal thickness was found ([@b59-co-2-517]).

The most common systemic adverse event was taste perversion, occurring in 3.0%--7.8% of patients ([@b53-co-2-517]; [@b45-co-2-517]; [@b49-co-2-517]). There were no clinically significant changes from baseline in heart rate and blood pressure, and in laboratory values for hematology, blood chemistry, or urinalysis variables. In addition, mean total carbonic anhydrase activity in red blood cells was reduced by only 51%--55%. However, one case of systemic metabolic acidosis has been described by [@b37-co-2-517].

Brinzolamide has been introduced to treat OH and primary open-angle glaucoma (POAG), which are probably two different aspects of the same disease in which IOP is too high for the optic nerve head (ONH) structure.

Glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. Clinically, the glaucomatous optic nerve manifests progressive enlargement of the optic cup, with commensurate progressive thinning of the neuroretinal rim and visual field defects. However, it is possible to lose up to 35% of optic nerve axons before the first visual field defect is detectable using standard automated perimetry ([@b41-co-2-517]; [@b60-co-2-517]).

OH is characterized by an increase of IOP without any visual field, ONH, and retinal nerve fibre layer changes ([@b11-co-2-517]). In other words OH can be a first step forward the glaucoma in most patients, but not all OH patients will change to glaucoma. Indeed, in the ocular hypertension treatment study (OHTS), it was found that after a follow-up of 5 or 7 years some OH subjects changed to glaucoma even if patients were treated or not ([@b57-co-2-517]). Obviously the percentage was different and in particular among the OH patients treated with topical hypotonic medication about 5% changed to glaucoma, while in the other group which did not receive any medication the percentage change was 9% ([@b26-co-2-517]). However, it is still not clear when and which OH patients need to be treated.

Both in POAG and OH patients, the main risk factor for progression is an elevated IOP which can cause damage to the ONH and then to the visual field. Some clinical trials have shown that decreasing the IOP can be useful for slowing down glaucoma progression ([@b7-co-2-517]; [@b2-co-2-517]; Kass et al 2001; [@b21-co-2-517]; [@b33-co-2-517]), and IOP has been the only treatable risk factor until now ([@b11-co-2-517]). Thus the treatment of glaucoma focuses on the reduction of IOP with drugs, lasers, or surgery. Over the past few years, there has been a gradual shift in the choice of first-line medical therapy. Six different classes of IOP-lowering molecules are currently available, including alpha adrenergic agonists, beta-blockers, CAI, parasympathomimetics, prostaglandin analogues, and sympathomimetics. The efficacy differs among these classes, ranging from about 30% for the prostaglandins/prostamides to about 18% for the topical CAI ([@b11-co-2-517]).

Clinically, all types of IOP-lowering medications can be used as the first choice, as European Glaucoma Society guidelines suggest. If the first-chosen medication alone does not control glaucoma, adjunctive therapy in the form of other topical agents can be added to the therapeutic regimen. However, when the first choice is not effective and/or tolerated in any individual patient, any of the other topical agents can be substituted as monotherapy.

When choosing the medical treatment for glaucoma, it is important to understand not only the aims of therapy, but also the mode of action, side effects, and contraindications of each individual medication ([@b11-co-2-517]). Many antiglaucoma drugs are available, and the choice of therapy must take into account quality of life, cost, and compliance. If more than two topical medications are required to control the IOP, other forms of therapy, such as laser trabeculoplasty, or surgery, should be considered.

The reduction of IOP can differ based on the IOP baseline; however, the CNTGS showed that the reduction should be at least 30% to slow glaucoma progression ([@b7-co-2-517]). In contrast the AGIS Investigators showed that in the group of patients that maintained IOP at around 12 mmHg in all examinations during the 7-year follow-up, visual field did not progress ([@b43-co-2-517]). [@b33-co-2-517] evaluated separately patients with higher and lower baseline IOP to determine progression factors at the end of the Early Manifest Glaucoma Trial (EMGT) based on all EMGT patients. Patients with early open-angle glaucoma were randomized to argon laser trabeculoplasty plus betaxolol or no immediate treatment, and examined every 3 months for up to 11 years. Treatment and follow-up continued to have a marked influence on IOP progression, regardless of baseline IOP. Other significant factors were age, bilaterality, exfoliation, and disc hemorrhages. Lower systolic perfusion pressure, lower systolic blood pressure, and cardiovascular disease history emerged as new predictors, suggesting a vascular role in glaucoma progression. A new risk factor was a thinner central corneal thickness ([@b33-co-2-517]), but its role is still under debate as a confounding factor.

Also the OHTS showed that topical ocular hypotensive medication is effective in delaying or preventing the onset of POAG in individuals with elevated IOP (OH) and no evidence of glaucomatous damage ([@b11-co-2-517]).

These data show that IOP reduction is fundamental in POAG and OH to delay the onset or prevent the onset of POAG in OH or the progression of the damage in POAG. Brinzolamide can be used alone or in combination with other medication to treat these patients.

The main ocular effect of brinzolamide is on IOP: in the ciliary epithelium, the inhibition of CA-II slows the formation of bicarbonate ions and their secretion into the posterior chamber of the eye. This reduces the sodium transport into the posterior chamber and decreases aqueous humor production, resulting in lower IOP ([@b35-co-2-517]). Interestingly, CA is a highly efficient enzyme, and it has been estimated that more than 99% of CA activity must be inhibited in order to suppress aqueous production to lower IOP measurably ([@b35-co-2-517]). The efficacy of brinzolamide 1% and dorzolamide 2% was compared in 25 normal subjects: brinzolamide reduced daytime aqueous flow by 0.47 μL/min and night-time aqueous flow by 0.16 μL/min, while dorzolamide reduced aqueous flow by 0.34 μL/min and by 0.10 μL/min, respectively. However, the relative reductions of aqueous flow achieved by brinzolamide and dorzolamide were similar for both medications ([@b25-co-2-517]).

In monotherapy
==============

In a meta-analysis, [@b57-co-2-517] estimated the IOP reduction achieved by the most frequently prescribed glaucoma drugs and a placebo in a meta-analysis of randomized clinical trials: they found that the highest reduction of IOP achieved by brinzolamide was of 17%.

[@b59-co-2-517] conducted a small, prospective, double-masked study comparing brinzolamide 1% bid with timolol 0.5% bid in 50 patients with open-angle glaucoma. After 6 weeks of treatment, IOP dropped 4.8 mmHg (17%) in brinzolamide-treated eyes and 5.7 mmHg (19.7%) in timolol-treated eyes (p \> 0.05).

Adjunctive to beta-blocker
==========================

[@b49-co-2-517] compared the efficacy of brinzolamide 1% (tid) and timolol 0.5% (bid) to timolol 0.5 (bid) and placebo (tid) in patients with open-angle glaucoma or OH. After 1 month of timolol, patients added either brinzolamide or placebo for 3 months; mean IOP reductions after the addition of brinzolamide to timolol ranged from 3.3 to 4.1 mmHg (statistically significant compared with both baseline and placebo).

Adjunctive to prostaglandin
===========================

As we well know, prostaglandin derivatives improve uveoscleral outflow, but they also increase the activity of CA in ciliary epithelium with a secondary increase in aqueous humor secretion ([@b36-co-2-517]), causing a slight reduction in the efficacy of prostaglandin analogues. Theoretically, topical CAI decrease IOP by inhibiting CA-II ([@b10-co-2-517]), thus improving prostaglandin efficacy as well as reducing IOP.

Clinically in all adjunctive studies, a significant reduction of IOP was observed. [@b50-co-2-517] added brinzolamide to once-daily latanoprost 0.005% in a small (n = 14), uncontrolled, open-label study of POAG. Mean IOP significantly (p \< 0.01) decreased by 20%, 21.1%, and 23.5% after 1, 2, and 3 months of treatment, respectively. Also in patients with normal-tension glaucoma, [@b39-co-2-517] compared the efficacy of latanoprost alone in one eye with latanoprost plus brinzolamide in the fellow eye. Mean diurnal (p \< 0.001) and nocturnal (p \< 0.05) IOP and the mean circadian IOP reduction from washout (p \< 0.01) were significantly reduced more in the brinzolamide adjunct group (17.1%) than the latanoprost monotherapy group (13.6%).

In a multicenter, randomized, double-masked, parallel group comparison study, [@b14-co-2-517] compared the effect of brinzolamide 1% bid or timolol 0.5% bid when added to travoprost. After 3 months, no significant (p = 0.96) difference in the IOP reduction was found between groups. [@b22-co-2-517] found that patients receiving combined travoprost ophthalmic solution 0.004% and brinzolamide ophthalmic suspension 1% therapy had lower IOP values than those on travoprost monotherapy (p \< 0.0001). Combined therapy resulted in a significantly greater percentage of patients achieving IOP of 18 mmHg or less (p \< 0.0001).

[@b13-co-2-517] compared the efficacy of brinzolamide 1% bid with brimonidine 0.15% bid when added to travoprost once daily: after 3 months of treatment, a reduction of 2.7 mmHg was found in the brinzolamide group and of 2.1 mmHg in the brimonidine group (significant, p = 0.035).

[@b43-co-2-517] compared the additive efficacies of brinzolamide 1%, brimonidine 0.2%, or timolol 0.5%, each dosed twice daily, when added to travoprost 0.004% once daily. Mean adjunctive IOP reduction seen with brinzolamide (4.2 mmHg, 22.7%) was statistically equivalent to that seen with timolol (3.9 mmHg, 20.2%) (p \> 0.05) and both were significantly (p \< 0.02) greater than that seen with brimonidine (2.3 mmHg, 13.4%).

[@b36-co-2-517] compared the IOP-lowering efficacy of concomitant therapy with travoprost once daily and brinzolamide twice daily versus once-daily dosing of the latanoprost/timolol fixed combination. Mean diurnal IOP was lower in the travoprost plus brinzolamide group than in the latanoprost/timolol group at 1 month (p = 0.041), 2 months (p = 0.046), and 3 months (p = 0.015). The IOP differences ranged from 0.8 to 1.2 mmHg.

However, there is some published evidence that the pathophysiology of glaucoma is multifactorial, and that impaired blood flow has a role in the disease process ([@b31-co-2-517]; [@b56-co-2-517]; [@b4-co-2-517]; [@b42-co-2-517]). Low diastolic perfusion pressure has been linked to a higher incidence of glaucoma in a population-based study. Furthermore, disc hemorrhage has been identified as a risk factor for disease progression in several studies ([@b5-co-2-517]; [@b32-co-2-517]). Also, conditions related to vasospasm are sometimes found in patients with glaucoma, especially in normal-tension glaucoma. Vascular dysregulation could be one of the most important prognostic factors for following some patients. The inconstant ONH perfusion could activate the astroglia to produce some molecules that normally they do not produce or produce in low levels ([@b17-co-2-517]).

As [@b47-co-2-517] showed, the use of the magic number of 21 mmHg to divide normal-tension glaucoma (NTG) from high-tension glaucoma (HTG) is not sufficient: indeed they found that other risk factors could be useful to divide POAG subgroups. Similar results using a different approach were obtained by [@b40-co-2-517] who reviewed about 1000 ONH slides of glaucomatous patients to divide them into 4 glaucomatous subgroups: focal ischemic glaucoma, senile glaucoma, myopic glaucoma, and concentric excavation glaucoma. They selected about 100 pure aspect optic discs that were included in one of these four subgroups. Finally, they checked the clinical features of each subgroup and found significant differences in IOP values, vasospatic symptoms, and visual field defects, suggesting that IOP was still an important risk factor to treat, but other factors were involved in the pathogenesis of the disease.

Brinzolamide could have a secondary possible effect on ocular flow. [@b46-co-2-517] compared the ONH circulation in healthy eyes, OH, and glaucoma eyes and found that blood flow was decreased in OH and glaucoma eyes compared with normal ones. Brinzolamide restored ONH blood flow to normal levels in OH eyes, but it did not change with brinzolamide therapy, most probably due to the loss of connective tissue.

However, [@b30-co-2-517] investigated the potential in vivo influence of different topical glaucoma medications on the diameter of retinal arterioles of healthy volunteers and glaucoma patients through the use of a retinal vessel analyzer (RVA, Imedos GmbH, Weimar, Germany) and found no significant changes in arteriole diameter at 2 hours after instillation of the topical antiglaucoma drugs (ie, brinzolamide 1%, timolol 0.5%, betaxolol 0.5%, brimonidine 0.2%, latanoprost 0.005%).

[@b52-co-2-517] reported that eyes with POAG, treated with brinzolamide, benefited from higher diastolic perfusion pressures than eyes treated with dorzolamide. Thirteen subjects were enrolled in a masked crossover study consisting of 3 months of therapy with each drug. There were no statistically significant differences in IOP, heart rate, mean arterial pressure, or systolic blood pressure, but diastolic perfusion pressure was higher in left eyes (although comparable in right eyes) of subjects treated with brinzolamide versus dorzolamide.

Using the Heidelberg Retina Flowmeter in a prospective study on 20 glaucomatous patients, [@b23-co-2-517] found that after brinzolamide treatment a 19% decrease in IOP was obtained and a concomitant improvement of the retinal blood flow was obtained at the superior and inferior peripapillary area. The improvement of the retinal blood flow ranged from 13.15 % to 16.6%. In 30 normal human volunteers, [@b27-co-2-517] found that eyes treated with brinzolamide had no measurable changes in retrobulbar hemodynamic by color Doppler, but did show a significantly reduced arteriovenous passage time compared with placebo, as determined by video fluorescein angiogram.

Theoretically, CAI could give rise to metabolic acidosis, with secondary vasodilatation and improvement of blood flow. Systemic acidosis can occur in the setting of oral CAI therapy, and local acidosis within ocular tissues is theoretically possible with topical CAI therapy, with the potential for a local increase in ocular blood flow ([@b28-co-2-517]). Topical and systemic CAI have been shown to improve parameters related to ocular blood flow ([@b18-co-2-517], [@b19-co-2-517]; [@b3-co-2-517]). In particular, because systemic CAI also results in altered CO~2~ clearance and pH levels ([@b55-co-2-517]), an increase in tissue PCO~2~ might promote local vasodilatation. Furthermore, several authors found that acetazolamide is capable of increasing cerebral blood flow in a dose-dependent manner, which was attributed to extracellular acidification ([@b48-co-2-517]; [@b20-co-2-517]; [@b58-co-2-517]; [@b12-co-2-517]; [@b44-co-2-517]).

Even if local CAIs accumulate inside the red blood cells because of their high affinity for some proteins of red cells and plasma ([@b18-co-2-517]; [@b8-co-2-517]), it has been shown that topical CAI did not affect the retrobulbar hemodynamic parameters, while they enhanced the retinal blood flow velocity indices, improved retinal blood flow, and increased the capillary velocity in the superficial vessels of the ONH.

Several studies have shown blood flow or blood velocity differences between normal healthy subjects and glaucomatous ones ([@b15-co-2-517]; [@b16-co-2-517]); and epidemiological studies have disclosed an increased risk for glaucoma when ocular perfusion was low ([@b56-co-2-517]; [@b4-co-2-517]). Therefore, the secondary vasoactive effect of brinzolamide could be useful in glaucoma since evidence is growing that in some glaucoma patients vascular dysregulation and lower perfusion pressure are important risk factors ([@b18-co-2-517], [@b19-co-2-517]; [@b6-co-2-517]).

In conclusion, topical CAI treatment has an efficacy in IOP-lowering that ranges from 15% to 20%. Published data show that brinzolamide can be used as first-line medication, even if other medications have a higher efficacy, with few side effects, and that it is a good adjunctive treatment. In those patients in which IOP must be reduced more than 30%, brinzolamide can be combined with either prostaglandin analogues or with beta-blockers. In the near future new formulations with brinzolamide will be on the market. In particular it will be combined with a beta-blocker or a prostaglandin analogue. In the former fixed combination, both molecules work to decrease IOP by suppressing the production of aqueous humor, but in the latter the target of the two medications to decrease IOP is different. In particular, topical CAI should be able to inhibit the activity of CA in the ciliary epithelium which the prostaglandins tend to increase ([@b50-co-2-517]; Nakamoto and Franks 2006; [@b39-co-2-517]).

In some types of glaucoma patients with a vascular dysregulation, topical CAI could have a double effect: to reduce the IOP and to improve the ocular blood flow. However, it is still controversial whether topical CAI can improve ocular blood flow, and we have to consider the possibility that the improvement of the ocular flow could be also be due to simply IOP reduction. Even if some clinical studies showed that brinzolamide could improve blood flow, no long-term trial has been performed to answer this question.
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